Decreasing candidaemia rate in abdominal surgery patients after introduction of fluconazole prophylaxis

Clinical Microbiology and Infection

Volumn 17, Issue 9, 2011, Pages 1372-1380

  Holzknecht, B J ^a   Thorup, J ^b   Arendrup, M C ^c   Andersen, S E ^b   Steensen, M ^a   Hesselfeldt, P ^a   Nielsen, J M ^b   Knudsen, J D ^a  

^a Mental Health Center Glostrup   (Denmark)

^b BISPEBJERG HOSPITAL   (Denmark)

^c STATENS SERUM INSTITUT   (Denmark)

Author keywords

Abdominal surgery; Candidaemia; Fluconazole; Gastrointestinal tract perforation; Prophylaxis

Indexed keywords

AMPICILLIN; CEFUROXIME; CIPROFLOXACIN; FLUCONAZOLE; GENTAMICIN; METRONIDAZOLE; PIPERACILLIN PLUS TAZOBACTAM;

ABDOMINAL SURGERY; ADULT; AGED; ANTIBIOTIC PROPHYLAXIS; ANTIFUNGAL RESISTANCE; ARTICLE; CANDIDA ALBICANS; CANDIDA GLABRATA; CANDIDA KRUSEI; CANDIDA TROPICALIS; CANDIDEMIA; CHEMOPROPHYLAXIS; CLINICAL TRIAL; DRUG SUBSTITUTION; DRUG UTILIZATION; FEMALE; FOLLOW UP; HOSPITAL ADMISSION; HUMAN; INFECTION RATE; INTENSIVE CARE UNIT; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SURGICAL PATIENT;

EID: 79957932788     PISSN: 1198743X     EISSN: 14690691     Source Type: Journal    
DOI: 10.1111/j.1469-0691.2010.03422.x     Document Type: Article

References (30)

1. Pfaller MA, Diekema DJ. Epidemiology of invasive candidiasis: a persistent public health problem. Clin Microbiol Rev 2007; 20: 133-163.
2. Tortorano AM, Peman J, Bernhardt H et al. Epidemiology of candidaemia in Europe: results of 28-month European Confederation of Medical Mycology (ECMM) hospital-based surveillance study. Eur J Clin Microbiol Infect Dis 2004; 23: 317-322.
3. Gudlaugsson O, Gillespie S, Lee K et al. Attributable mortality of nosocomial candidemia, revisited. Clin Infect Dis 2003; 37: 1172-1177.
4. Hassan I, Powell G, Sidhu M, Hart WM, Denning DW. Excess mortality, length of stay and cost attributable to candidaemia. J Infect 2009; 59: 360-365.
5. Nucci M, Anaissie E. Revisiting the source of candidemia: skin or gut? Clin Infect Dis 2001; 33: 1959-1967.
6. Morrell M, Fraser VJ, Kollef MH. Delaying the empiric treatment of Candida bloodstream infection until positive blood culture results are obtained: a potential risk factor for hospital mortality. Antimicrob Agents Chemother 2005; 49: 3640-3645.
7. Garey KW, Rege M, Pai MP et al. Time to initiation of fluconazole therapy impacts mortality in patients with candidemia: a multi-institutional study. Clin Infect Dis 2006; 43: 25-31.
8. Garbino J, Lew DP, Romand JA, Hugonnet S, Auckenthaler R, Pittet D. Prevention of severe Candida infections in nonneutropenic, high-risk, critically ill patients: a randomized, double-blind, placebo-controlled trial in patients treated by selective digestive decontamination. Intensive Care Med 2002; 28: 1708-1717.
9. Eggimann P, Francioli P, Bille J et al. Fluconazole prophylaxis prevents intra-abdominal candidiasis in high-risk surgical patients. Crit Care Med 1999; 27: 1066-1072.
10. Pelz RK, Hendrix CW, Swoboda SM et al. Double-blind placebo-controlled trial of fluconazole to prevent candidal infections in critically ill surgical patients. Ann Surg 2001; 233: 542-548.
11. Ables AZ, Blumer NA, Valainis GT, Godenick MT, Kajdasz DK, Palesch YY. Fluconazole prophylaxis of severe Candida infection in trauma and postsurgical patients: a prospective, double-blind, randomized, placebo-controlled trial. Infect Dis Clin Pract 2000; 9: 169-175.
12. Savino JA, Agarwal N, Wry P, Policastro A, Cerabona T, Austria L. Routine prophylactic antifungal agents (clotrimazole, ketoconazole, and nystatin) in nontransplant/nonburned critically ill surgical and trauma patients. J Trauma 1994; 36: 20-26.
13. Sandven P, Qvist H, Skovlund E, Giercksky KE, NORGAS Group and the Norwegian Yeast Study Group. Significance of Candida recovered from intraoperative specimens in patients with intra-abdominal perforations. Crit Care Med 2002; 30: 541-547.
14. Shorr AF, Chung K, Jackson WL, Waterman PE, Kollef MH. Fluconazole prophylaxis in critically ill surgical patients: a meta-analysis. Crit Care Med 2005; 33: 1928-1935.
15. Cruciani M, de Lalla F, Mengoli C. Prophylaxis of Candida infections in adult trauma and surgical intensive care patients: a systematic review and meta-analysis. Intensive Care Med 2005; 31: 1479-1487.
16. Playford EG, Webster AC, Sorrell TC, Craig JC. Antifungal agents for preventing fungal infections in non-neutropenic critically ill and surgical patients: systematic review and meta-analysis of randomized clinical trials. J Antimicrob Chemother 2006; 57: 628-638.
17. Piarroux R, Grenouillet F, Balvay P et al. Assessment of preemptive treatment to prevent severe candidiasis in critically ill surgical patients. Crit Care Med 2004; 32: 2443-2449.
18. Shan YS, Sy ED, Wang ST, Lee JC, Lin PW. Early presumptive therapy with fluconazole for occult Candida infection after gastrointestinal surgery. World J Surg 2006; 30: 119-126.
19. Schuster MG, Edwards JE Jr, Sobel JD et al. Empirical fluconazole versus placebo for intensive care unit patients: a randomized trial. Ann Intern Med 2008; 149: 83-90.
20. Guery BP, Arendrup MC, Auzinger G et al. Management of invasive candidiasis and candidemia in adult non-neutropenic intensive care unit patients: Part II, Treatment. Intensive Care Med 2009; 35: 206-214.
21. Pappas PG, Kauffman CA, Andes D et al. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis 2009; 48: 503-535.
22. Solomkin JS, Mazuski JE, Bradley JS et al. Diagnosis and management of complicated intra-abdominal infection in adults and children: guidelines by the Surgical Infection Society and the Infectious Diseases Society of America. Clin Infect Dis 2010; 50: 133-164.
23. Montravers P, Dupont H, Gauzit R et al. Candida as a risk factor for mortality in peritonitis. Crit Care Med 2006; 34: 646-652.
24. Chow JK, Golan Y, Ruthazer R et al. Factors associated with candidemia caused by non-albicans Candida species versus Candida albicans in the intensive care unit. Clin Infect Dis 2008; 46: 1206-1213.
25. Arendrup MC, Fuursted K, Gahrn-Hansen B et al. Semi-national surveillance of fungaemia in Denmark 2004-2006: increasing incidence of fungaemia and numbers of isolates with reduced azole susceptibility. Clin Microbiol Infect 2008; 14: 487-494.
26. Subcommittee on Antifungal Susceptibility Testing (AFST) of the ESCMID European Committee for Antimicrobial Susceptibility Testing (EUCAST). EUCAST definitive document EDef 7.1: method for the determination of broth dilution MICs of antifungal agents for fermentative yeasts. Clin Microbiol Infect 2008; 14: 398-405.
27. European Committee on Antimicrobial Susceptibility Testing-Subcommittee on Antifungal Susceptibility Testing (EUCAST-AFST). EUCAST technical note on fluconazole. Clin Microbiol Infect 2008; 14: 193-195.
28. Clinical and Laboratory Standards Institute (CLSI). Reference method for broth dilution antifungal susceptibility testing of yeasts; approved standard. CLSI document M27-A3, 3nd edn. Wayne, PA: CLSI, 2008. ISBN 1-56238-666-2.
29. Brion LP, Uko SE, Goldman DL. Risk of resistance associated with fluconazole prophylaxis: systematic review. J Infect 2007; 54: 521-529.
30. Swoboda SM, Merz WG, Lipsetta PA. Candidemia: the impact of antifungal prophylaxis in a surgical intensive care unit. Surg Infect (Larchmt) 2003; 4: 345-354.